are members of one or more of the following three organizations: the American Society for Pharmacology and Experimental Therapeutics (ASPET), the American Society for Clinical Pharmacology and Therapeutics (ASCPT), and the American College of Clinical Pharmacology ( A C C P ) . T h e American Board of Clinical Pharmacology was founded in 1976, but to date no certifying examinations have been conducted, partly due to lack of agreement among the three concerned organizations. While the ACCP was instrumental in incorporating the board, all three groups are now represented on a task force to ( 1 ) define clinical pharmacology, (2) determine goals for the discipline, (3) describe appropriate training programs, and (4) evaluate mechanisms for certifying clinical pharmacologists. 1 One clear and stated intent of the board is to establish clinical pharmacology as a medical specialty, and to certify as clinical pharmacologists only physicians who have met specific training standards.
I would like to raise several fundamental questions and issues in regard to these contemplated actions. They are as follows :
1. Is there a sufficiently large nucleus of physicians with similar training and skills, along with a primary identity with clinical pharmacology, to form a medical specialty?
2. Do these clinical pharmacologists possess drug research and consultative skills not possessed by a large number of physicians who are not primarily identified with clinical pharmacology?
3. Why should pharmaceutical scientists performing important and pioneering clinical research in biopharmaceutics and pharmacokinetics not be considered eligible for certification as clinical pharmacologists ?
4. Is the patient-care function performed by clinical pharmacologists sufficiently large and important to justify board certification and a differentiation from other physicians or health-care professionals?
A few comments on medical specialization are in order before considering these questions. T h e A M A has established the Board of Medical Specialties to control the formal recognition of medical specialties. In addition, there is an independent corporation named the American Board of Medical Examiners whose function is to provide, on a contractual basis, an examination service to client specialty organizations. It is certainly the prerogative of physician pharmacologists to attempt to develop a physician-only specialty, and the A M A would not recognize a specialty that contained nonphysicians.
There are several dozen physicians in the U.S. and Canada whose primary identity is with clinical pharmacology. Many of the members of ASPET, ASCPT, and ACCP are more strongly identified with other specialty or subspecialty areas -e.g., pediatrics, nephrology, cardiology,' or neurology. They may or may not desire to achieve board certification in clinical pharmacology. While there is a nucleus of clinical pharmacologists, the number is relatively small and is not rapidly increasing. Many of this nucleus have important administrative duties as pharmacology department heads or industry research coordinators. Board certification would, however, offer distinct advantages to clinical pharmacology and to those certified by the board, particularly to younger, unestablished individuals.
Clinical pharmacologists undoubtedly possess greater drug research and therapeutic consultative skills than the nonacademic generalists in internal medicine, surgery, pediatrics, family practice, and psychiatry. There are many physicians, however, who are experts in therapeutics and drug research in subspecialty areas, and general clinical pharmacologists could contribute very little as consultants to these specialists. Clinical pharmacists have experienced this type of situation in many teaching hospitals.
A large and important component of clinical pharmacology is pharmacokinetics, one of the areas probably least understood by practicing physicians. Scientists in pharmacy have contributed greatly to the theoretical and practical development of this knowledge, and pharmacy clinicians with good scientific orientation are participating to an increasing extent in the advancement of clinical pharmacology knowledge. Should these persons be eligible for certification? The answer is no if clinical pharmacology is to be a medical specialty; however, this restriction would not prevent pharmacy clinicians and scientists from participating in the clinical pharmacology organizations.
The usual justification of physician certification has been that certain practitioners become sufficiently expert in a narrow area of medicine (patient care) that they become differentiated from other physicians. Certification is a means of recognizing this expertise, and of protecting the patient from those who wish EDITORIAL to claim the expertise but do not have the credentials. The process is obviously both self-serving and patientserving.
Clinical pharmacologists generally provide only a small amount of direct patient care. Much of their time is spent in research and academic duties, and their patient-care function is obvious in only a few teaching hospitals in the nation. Even many medical schools and teaching hospitals do not have a clinical pharmacology service, and it is very rare in other facilities, except in the form of drug-company-sponsored research programs. Thus, the argument that board certification is needed to protect the patient from inappropriate pharmacologie therapy does not seem defensible today. There will probably not, in the near future, be a clinical pharmacologist between Minneapolis and Seattle, board certification or not! It seems appropriate, and indeed wise, for physicianclinical pharmacologists to establish a board certification process. Although it is regrettable that qualified pharmacy clinicians and scientists would not be considered for certification, it is not possible as long as clinical pharmacology is viewed as a medical specialty under the auspices of the AMA. From a patient-care point of view, it is more important that there be a high-level certification process in clinical pharmacy than in clinical pharmacology, since the former has many more clinicians providing a far greater volume of therapeutic consultative and advisory services. With the current lack of standards and greatly varying educational and training backgrounds, the patient needs the protection of a meaningful certification process in clinical pharmacy. It remains highly important that clinical pharmacists contribute in an exemplary way to clinical pharmacology and medical specialty organizations and publications. Only through these contributions and those in the patient-care arena will the colleagueship and partnership be forged that are critical to advancing the quality of drug therapy in society.
